BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Prima Biomed (PRR.AX) to Release Interim CVac Clinical Data


7/30/2012 9:11:26 AM

SYDNEY, AUSTRALIA--(Marketwire - July 29, 2012) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (Prima, the Company) announces that it will be releasing interim results from its CVac™ clinical trial CAN-003 in October 2012.

The International Gynecologic Cancer Society (IGCS) has accepted an abstract by Dr. Jeffrey Goh et al. entitled "Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer in first or second remission" for a poster presentation at its biennial meeting in Vancouver, Canada from October 13-16, 2012.

Dr. Goh's poster will present interim safety and progression-free survival (PFS) data from the CAN-003 trial based on a currently ongoing analysis.

Intracellular cytokine staining (ICS) results for the first cohort of 6 patients who completed full dosing will also be released in early October 2012. ICS is a laboratory technique to evaluate if CVac has induced the desired mucin 1-specific T-cell response in treated patients. ICS results help to confirm the biological activity of CVac. Positive ICS results would validate the continuing development in ovarian cancer trials and potentially pave the way for Prima to commence exploratory trials in other cancer types that overexpress mucin-1.

CAN-003 is a 63-patient phase 2 trial of CVac in epithelial ovarian cancer patients in complete remission after successful first or second line chemotherapy. 36 patients were randomized to CVac treatment and 27 patients were assigned to observational standard of care. Patient enrollment into the study commenced in July 2010 and was completed in September 2011. The last patient will receive the final dose of CVac in October 2012 and patients will continue to be followed until at least October 2013.

Prima will provide further updates on ICS data from further patient cohorts as results are available over the next year. Final data analysis of CAN-003, including PFS, safety, and other endpoints, is anticipated in Q4 2013.

Prima BioMed CEO designate Matthew Lehman said: "We are pleased to provide a timetable of data points for the CAN-003 study. Dosing of patients on the trial is drawing to a close and we look forward to sharing these important results over the coming months."

Expected CAN-003 study data timetable:

October 2012: Final (63rd) patient receives final dose of CVac

Early October 2012: ICS data from the first 6 patients who completed dosing

October 15 2012: Interim safety and PFS data presented by Dr. Goh at the IGCS conference in Vancouver, Canada.

Throughout 2013: Updates on ICS data from subsequent cohorts of patients.

4th Quarter 2013: Final data analysis per protocol of safety, PFS, and other endpoints.

About Prima BioMed

Prima BioMed is a globally active biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.

About CAN-003

CAN-003 is an open label, randomized, multinational and controlled clinical study in a Phase II setting. 63 ovarian cancer patients in 1st or 2nd remission have been enrolled, with 36 patients in the CVac group compared to 27 patients in the observation group.


For further information please contact:

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

USA Investor/Media:
Ms. Kathy Galante
Burns McClellan Inc.
+1 (212) 213-0006
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES